RT Journal Article
SR Electronic
T1 Evaluating the Risk of Psilocybin for the Treatment of Bipolar Depression: A Review of the Research Literature and Published Case Studies
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2021.04.02.21254838
DO 10.1101/2021.04.02.21254838
A1 Gard, David E.
A1 Pleet, Mollie M.
A1 Bradley, Ellen R.
A1 Penn, Andrew
A1 Gallenstein, Matthew L.
A1 Riley, Lauren S.
A1 DellaCrosse, Meghan
A1 Garfinkle, Emily
A1 Michalak, Erin E.
A1 Woolley, Joshua D.
YR 2021
UL http://medrxiv.org/content/early/2021/04/17/2021.04.02.21254838.abstract
AB Growing evidence suggests that psilocybin, the active ingredient in hallucinogenic mushrooms, can rapidly and durably improve symptoms of depression, leading to recent breakthrough status designation by the FDA and legalization for mental health treatment in some jurisdictions. Depression in bipolar disorder is associated with significant morbidity and has few effective treatments. However, there is a dearth of available scientific data on the risk of psilocybin use in bipolar disorder. Individuals with bipolar disorder have been excluded from modern clinical trials, out of understandable concerns of activating mania or worsening the illness course. As psilocybin becomes more available, people with these disorders will likely seek psilocybin treatment for depression and have likely been doing so in unregulated settings. Our goal was to summarize the known risks of psilocybin use (and similar substances) in bipolar disorder and to systematically evaluate the examples of published case history data, in order to critically evaluate the relative risk of psilocybin as a treatment for bipolar depression. We found 15 possible cases suggesting that there is potential risk for activating a manic episode, thereby warranting caution. Nonetheless, the relative lack of systematic data or common case examples indicating risk appears to show that a cautious trial, using modern trial methods focusing on appropriate ‘set’ and ‘setting’, targeted at those lowest at risk for mania in the bipolar spectrum (e.g., bipolar 2 disorder), is very much needed, especially given the degree to which depression impacts this population.Sources of direct funding, support, or sponsorshipDr. Woolley is funded in part via VA CSR&D 1IK4CX002090-01. Grant title: Quantifying and Treating Social Deficits in Veterans with Mental Illness: a Five Year Plan.Role of the sponsorNot applicablePotential conflicts of interestDr. Woolley is a paid consultant for Psilo Scientific Ltd. and Silo Pharma.Competing Interest StatementDr. Woolley is a paid consultant for Psilo Scientific Ltd. and Silo Pharma. Funding StatementDr. Woolley is funded in part via VA CSR&D 1IK4CX002090-01. Grant title: Quantifying and Treating Social Deficits in Veterans with Mental Illness: a Five Year Plan. Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:This is a review of the literature and no IRB approval was required.All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesNot applicable